A Prospective, Multicenter, Randomized PHASE II Clinical Trial of Enzalutamide Treatment to Decrease the Morbidity in Patients With Corona Virus Disease 2019 (COVID-19)
Latest Information Update: 21 Mar 2022
Price :
$35 *
At a glance
- Drugs Enzalutamide (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Acronyms COVIDENZA
- 01 Mar 2022 Results evaluating the effect of antiandrogens on SARS-CoV-2 infection in the European Urology
- 22 Aug 2021 Status changed from recruiting to discontinued.
- 20 Jul 2020 New trial record